Large granular lymphocytosis during dasatinib therapy

References

• Lamy T, Loughran TP. Large granular lymphocyte leukemia. Cancer Control 1998; 5:25 - 33; PMID: 10761014
   PubMedGoogle Scholar
• Loughran TP Jr.. Clonal diseases of large granular lymphocytes. Blood 1993; 82:1 - 14; PMID: 8324214
   PubMed Web of Science ®Google Scholar
• Sokol L, Loughran TP Jr.. Large granular lymphocyte leukemia. Oncologist 2006; 11:263 - 73; http://dx.doi.org/10.1634/theoncologist.11-3-263; PMID: 16549811
   PubMed Web of Science ®Google Scholar
• Zambello R, Semenzato G. Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches. Haematologica 2009; 94:1341 - 5; http://dx.doi.org/10.3324/haematol.2009.012161; PMID: 19794080
   PubMed Web of Science ®Google Scholar
• Lamy T, Bauer FA, Liu JH, Li YX, Pillemer E, Shahidi H, Gregory SA, Zambello R, Marcolongo R, Semenzato G, et al. Clinicopathological features of aggressive large granular lymphocyte leukaemia resemble Fas ligand transgenic mice. Br J Haematol 2000; 108:717 - 23; http://dx.doi.org/10.1046/j.1365-2141.2000.01934.x; PMID: 10792274
   PubMed Web of Science ®Google Scholar
• Chan WC, Foucar KM, Morice WG, Catovsky D. T-cell large granular lymphocyte leukaemia. In: WHO Classiication of Tumours of the Hematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL et al. (Eds). IARC Press, Lyon, France, 272–273 (2008).
   Google Scholar
• Villamor N, Morice WG, Chan WC, Foucar K. Chronic lyphoproliferative disorders of NK cells. In: WHO Classiication of Tumours of Hematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL et al. (Eds). IARC Press, Lyon, France, 274–275 (2008).
   Google Scholar
• Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109:5143 - 50; http://dx.doi.org/10.1182/blood-2006-11-056028; PMID: 17317857
   PubMed Web of Science ®Google Scholar
• Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109:3207 - 13; http://dx.doi.org/10.1182/blood-2006-09-046888; PMID: 17185463
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109:2303 - 9; http://dx.doi.org/10.1182/blood-2006-09-047266; PMID: 17138817
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7:345 - 56; http://dx.doi.org/10.1038/nrc2126; PMID: 17457302
   PubMed Web of Science ®Google Scholar
• Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, Perrin J, Raida M, Rau C, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007; 25:1035 - 44; http://dx.doi.org/10.1038/nbt1328; PMID: 17721511
   PubMed Web of Science ®Google Scholar
• Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, Schütze G, Colinge J, Bennett KL, Ellmeier W, Valent P, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 2007; 104:13283 - 8; http://dx.doi.org/10.1073/pnas.0702654104; PMID: 17684099
   PubMed Web of Science ®Google Scholar
• Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110:4055 - 63; http://dx.doi.org/10.1182/blood-2007-07-102061; PMID: 17720881
   PubMed Web of Science ®Google Scholar
• Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23:1398 - 405; http://dx.doi.org/10.1038/leu.2009.46; PMID: 19295545
   PubMed Web of Science ®Google Scholar
• Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010; 116:772 - 82; http://dx.doi.org/10.1182/blood-2009-12-256800; PMID: 20413659
   PubMed Web of Science ®Google Scholar
• Nagata Y, Ohashi K, Fukuda S, Kamata N, Akiyama H, Sakamaki H. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol 2010; 91:799 - 807; http://dx.doi.org/10.1007/s12185-010-0565-1; PMID: 20405252
   PubMed Web of Science ®Google Scholar
• Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, Lee JJ, Lipton JH. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 2009; 94:135 - 9; http://dx.doi.org/10.3324/haematol.13151; PMID: 19066329
   PubMed Web of Science ®Google Scholar
• Tanaka H, Nakashima S, Usuda M. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients. Int J Hematol 2012; 96:308 - 19; http://dx.doi.org/10.1007/s12185-012-1132-8; PMID: 22767140
   PubMed Web of Science ®Google Scholar
• Valent JN, Schiffer CA. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib. Leuk Res 2011; 35:e1 - 3; http://dx.doi.org/10.1016/j.leukres.2010.08.022; PMID: 20888043
   PubMedGoogle Scholar
• Lee SJ, Jung CW, Kim DY, Lee KH, Sohn SK, Kwak JY, Kim HJ, Kim IH, Park S, Kim DH. Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia. Am J Hematol 2011; 86:346 - 50; http://dx.doi.org/10.1002/ajh.21980; PMID: 21442637
   PubMed Web of Science ®Google Scholar
• Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, Sotomayor EM, Pinilla-Ibarz JA. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 2011; 52:668 - 79; http://dx.doi.org/10.3109/10428194.2010.550074; PMID: 21271862
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, Casazza JP, Kuruppu J, Migueles SA, Connors M, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003; 101:2711 - 20; http://dx.doi.org/10.1182/blood-2002-07-2103; PMID: 12433688
   PubMed Web of Science ®Google Scholar
• Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström S, Clemente MJ, Olson T, Jalkanen SE, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366:1905 - 13; http://dx.doi.org/10.1056/NEJMoa1114885; PMID: 22591296
   PubMed Web of Science ®Google Scholar
• Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, Olson T, Przychodzen B, Afable M, Gomez-Segui I, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 2012; 120:3048 - 57; http://dx.doi.org/10.1182/blood-2012-06-435297; PMID: 22859607
   PubMed Web of Science ®Google Scholar
• Jerez A, Clemente MJ, Makishima H, Rajala H, Gómez-Seguí I, Olson T, McGraw K, Przychodzen B, Kulasekararaj A, Afable M, et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. [Prepublished online] Blood 2013; 122:2453 - 9; http://dx.doi.org/10.1182/blood-2013-04-494930; PMID: 23926297
   PubMed Web of Science ®Google Scholar
• Smith PR, Cavenagh JD, Milne T, Howe D, Wilkes SJ, Sinnott P, Forster GE, Helbert M. Benign monoclonal expansion of CD8+ lymphocytes in HIV infection. J Clin Pathol 2000; 53:177 - 81; http://dx.doi.org/10.1136/jcp.53.3.177; PMID: 10823134
   PubMed Web of Science ®Google Scholar
• Schwab R, Szabo P, Manavalan JS, Weksler ME, Posnett DN, Pannetier C, Kourilsky P, Even J. Expanded CD4+ and CD8+ T cell clones in elderly humans. J Immunol 1997; 158:4493 - 9; PMID: 9127016
   PubMed Web of Science ®Google Scholar
• Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, Lahesmaa-Korpinen AM, Hautaniemi S, Bouchet S, Molimard M, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 2013; 27:914 - 24; http://dx.doi.org/10.1038/leu.2012.348; PMID: 23192016
   PubMed Web of Science ®Google Scholar
• Hassold N, Seystahl K, Kempf K, Urlaub D, Zekl M, Einsele H, Watzl C, Wischhusen J, Seggewiss-Bernhardt R. Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib. Int J Cancer 2012; 131:E916 - 27; http://dx.doi.org/10.1002/ijc.27537; PMID: 22419518
   PubMed Web of Science ®Google Scholar
• Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010; 85:387 - 98; http://dx.doi.org/10.1111/j.1600-0609.2010.01501.x; PMID: 20662899
   PubMed Web of Science ®Google Scholar
• Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L, Melo T, Einsele H, Porkka K, Price DA, et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011; 25:1587 - 97; http://dx.doi.org/10.1038/leu.2011.135; PMID: 21647156
   PubMed Web of Science ®Google Scholar
• Morelock SY, Sahn SA. Drugs and the pleura. Chest 1999; 116:212 - 21; http://dx.doi.org/10.1378/chest.116.1.212; PMID: 10424528
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99:3530 - 9; http://dx.doi.org/10.1182/blood.V99.10.3530; PMID: 11986204
   PubMed Web of Science ®Google Scholar
• Bergeron A, Réa D, Levy V, Picard C, Meignin V, Tamburini J, Bruzzoni-Giovanelli H, Calvo F, Tazi A, Rousselot P. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007; 176:814 - 8; http://dx.doi.org/10.1164/rccm.200705-715CR; PMID: 17600277
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian H, O’brien S, Borthakur G, Bruzzi J, Munden R, Cortes J. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25:3908 - 14; http://dx.doi.org/10.1200/JCO.2007.12.0329; PMID: 17761974
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH, Chaidos A, Olavarria E, Goldman JM, Apperley JF, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008; 141:745 - 7; http://dx.doi.org/10.1111/j.1365-2141.2008.07108.x; PMID: 18331365
   PubMed Web of Science ®Google Scholar
• Rossoff LJ, Genovese J, Coleman M, Dantzker DR. Primary pulmonary hypertension in a patient with CD8/T-cell large granulocyte leukemia: amelioration by cladribine therapy. Chest 1997; 112:551 - 3; http://dx.doi.org/10.1378/chest.112.2.551; PMID: 9266900
   PubMed Web of Science ®Google Scholar
• Chen X, Bai F, Sokol L, Zhou J, Ren A, Painter JS, Liu J, Sallman DA, Chen YA, Yoder JA, et al. A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood 2009; 113:3226 - 34; http://dx.doi.org/10.1182/blood-2008-07-168245; PMID: 19075187
   PubMed Web of Science ®Google Scholar
• Tajsic T, Morrell NW. Cellular and molecular mechanisms of pulmonary vascular smooth muscle cell proliferation In: Yuan JX-J, Garcia JGN, West JB, Hales CA, Rich S, Archer SL, editors. Textbook of pulmonary vascular disease. New York:Springer 2011.pp 323–334.
   Google Scholar
• Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, Szpurka H, Maciejewski JP. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111:1366 - 77; http://dx.doi.org/10.1182/blood-2007-04-084814; PMID: 17962511
   PubMed Web of Science ®Google Scholar
• Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008; 14:2484 - 91; http://dx.doi.org/10.1158/1078-0432.CCR-07-4393; PMID: 18413841
   PubMed Web of Science ®Google Scholar
• Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008; 111:4415 - 6; http://dx.doi.org/10.1182/blood-2008-02-138701; PMID: 18398058
   PubMed Web of Science ®Google Scholar
• Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008; 127:330 - 9; http://dx.doi.org/10.1016/j.clim.2008.02.006; PMID: 18395492
   PubMed Web of Science ®Google Scholar
• Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J, Götz M, Guillaume P, Döhner H, Bunjes D, et al. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp Hematol 2008; 36:1297 - 308; http://dx.doi.org/10.1016/j.exphem.2008.05.002; PMID: 18619726
   PubMed Web of Science ®Google Scholar
• Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol 2009; 37:256 - 65; http://dx.doi.org/10.1016/j.exphem.2008.09.013; PMID: 19056158
   PubMed Web of Science ®Google Scholar
• Seggewiss R, Loré K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105:2473 - 9; http://dx.doi.org/10.1182/blood-2004-07-2527; PMID: 15572591
   PubMed Web of Science ®Google Scholar
• Chen J, Schmitt A, Chen B, Rojewski M, Rübeler V, Fei F, Yu Y, Yu X, Ringhoffer M, von Harsdorf S, et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med 2008; 12:5B 2107 - 18; http://dx.doi.org/10.1111/j.1582-4934.2008.00234.x; PMID: 18194453
   PubMed Web of Science ®Google Scholar
• Blake SJ, Lyons AB, Hughes TP. Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro. J Cell Mol Med 2009; 13:599 - 601; http://dx.doi.org/10.1111/j.1582-4934.2009.00500_1.x; PMID: 19374687
   PubMed Web of Science ®Google Scholar
• Kelley TW, Parker CJ. CD4 (+)CD25 (+)Foxp3 (+) regulatory T cells and hematologic malignancies. [Schol Ed] Front Biosci (Schol Ed) 2010; 2:980 - 92; http://dx.doi.org/10.2741/S114; PMID: 20515837
   PubMedGoogle Scholar
• Zhang R, Shah MV, Yang J, Nyland SB, Liu X, Yun JK, Albert R, Loughran TP Jr.. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci U S A 2008; 105:16308 - 13; http://dx.doi.org/10.1073/pnas.0806447105; PMID: 18852469
   PubMed Web of Science ®Google Scholar
• Tayade C, Fang Y, Black GP, v A P Jr., Erlebacher A, Croy BA. Differential transcription of Eomes and T-bet during maturation of mouse uterine natural killer cells. J Leukoc Biol 2005; 78:1347 - 55; http://dx.doi.org/10.1189/jlb.0305142; PMID: 16204645
   PubMed Web of Science ®Google Scholar
• Ramirez K, Kee BL. Multiple hats for natural killers. Curr Opin Immunol 2010; 22:193 - 8; http://dx.doi.org/10.1016/j.coi.2010.02.002; PMID: 20335012
   PubMed Web of Science ®Google Scholar
• Gordon SM, Chaix J, Rupp LJ, Wu J, Madera S, Sun JC, Lindsten T, Reiner SL. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 2012; 36:55 - 67; http://dx.doi.org/10.1016/j.immuni.2011.11.016; PMID: 22261438
   PubMed Web of Science ®Google Scholar
• Tanaka J, Sugita J, Shiratori S, Shigematsu A, Imamura M. Dasatinib enhances the expansion of CD56+CD3- NK cells from cord blood. Blood 2012; 119:6175 - 6; http://dx.doi.org/10.1182/blood-2012-03-416800; PMID: 22730528
   PubMed Web of Science ®Google Scholar
• Montero JC, Seoane S, Ocaña A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 2011; 17:5546 - 52; http://dx.doi.org/10.1158/1078-0432.CCR-10-2616; PMID: 21670084
   PubMed Web of Science ®Google Scholar
• Eizuru Y, Minematsu T, Minamishima Y, Ebihara K, Takahashi K, Tamura K, Hosoda K, Masuho Y. Rapid diagnosis of cytomegalovirus infections by direct immunoperoxidase staining with human monoclonal antibody against an immediate-early antigen. Microbiol Immunol 1991; 35:1015 - 22; http://dx.doi.org/10.1111/j.1348-0421.1991.tb01623.x; PMID: 1663573
   PubMed Web of Science ®Google Scholar
• Gondo H, Minematsu T, Harada M, Akashi K, Hayashi S, Taniguchi S, Yamasaki K, Shibuya T, Takamatsu Y, Teshima T, et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. Br J Haematol 1994; 86:130 - 7; http://dx.doi.org/10.1111/j.1365-2141.1994.tb03263.x; PMID: 8011521
   PubMed Web of Science ®Google Scholar
• Al-Ameri A, Kantarjian H, Borthakur G, Bahceci E, Szatrowski T, Damokosh A, et al. Opportunistic infection are uncommon with dasatinib in patients with chronic myeloid leukemia in chronic phase (CP-CML). The 51th ASH Annual Meeting and Exposition 2009.
   Google Scholar
• Lowin-Kropf B, Kunz B, Schneider P, Held W. A role for the src family kinase Fyn in NK cell activation and the formation of the repertoire of Ly49 receptors. Eur J Immunol 2002; 32:773 - 82; http://dx.doi.org/10.1002/1521-4141(200203)32:3<773::AID-IMMU773>3.0.CO;2-U; PMID: 11870621
   PubMed Web of Science ®Google Scholar
• Gadue P, Morton N, Stein PL. The Src family tyrosine kinase Fyn regulates natural killer T cell development. J Exp Med 1999; 190:1189 - 96; http://dx.doi.org/10.1084/jem.190.8.1189; PMID: 10523617
   PubMed Web of Science ®Google Scholar
• Pignata C, Prasad KV, Hallek M, Druker B, Rudd CE, Robertson MJ, Ritz J. Phosphorylation of src family lck tyrosine kinase following interleukin-12 activation of human natural killer cells. Cell Immunol 1995; 165:211 - 6; http://dx.doi.org/10.1006/cimm.1995.1207; PMID: 7553885
   PubMed Web of Science ®Google Scholar
• Bloch-Queyrat C, Fondanèche MC, Chen R, Yin L, Relouzat F, Veillette A, Fischer A, Latour S. Regulation of natural cytotoxicity by the adaptor SAP and the Src-related kinase Fyn. J Exp Med 2005; 202:181 - 92; http://dx.doi.org/10.1084/jem.20050449; PMID: 15998796
   PubMed Web of Science ®Google Scholar
• Mellqvist UH, Hansson M, Brune M, Dahlgren C, Hermodsson S, Hellstrand K. Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. Blood 2000; 96:1961 - 8; PMID: 10961901
   PubMed Web of Science ®Google Scholar
• Chang WC, Hsiao MH, Pattengale PK. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, γ-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor. Nat Immun Cell Growth Regul 1991; 10:57 - 70; PMID: 1881400
   PubMedGoogle Scholar
• Pierson BA, Miller JS. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 1996; 88:2279 - 87; PMID: 8822949
   PubMed Web of Science ®Google Scholar
• Nakajima H, Zhao R, Lund TC, Ward J, Dolan M, Hirsch B, Miller JS. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients. J Immunol 2002; 168:643 - 50; PMID: 11777957
   PubMed Web of Science ®Google Scholar